MedTrace Logo

A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)

NCT04504032 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 497

Last updated 2021-10-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess safety and clinical efficacy of rivaroxaban in people with mild Coronavirus Disease 2019 who are at increased risk of disease progression.

Conditions

Interventions

DRUG

Rivaroxaban

Participants self-administered rivaroxaban, 10 milligrams (mg) (1 tablet) orally once daily for 21 days.

DRUG

Placebo

Participants self-administered rivaroxaban matching placebo orally once daily for 21 days.

Sponsors & Collaborators

  • Gates Medical Research Institute

    lead OTHER

Principal Investigators

  • GatesMRI · Gates Medical Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-02
Primary Completion
2021-03-10
Completion
2021-03-29
FDA Drug
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04504032 on ClinicalTrials.gov